Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis Meglumine in Transthyretin Amyloid Polyneuropathy (ATTR-PN)
NCT06940336Phase 4Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tafamidis in transthyretin amyloid polyneuropathy (ATTR-PN), sponsored by Qilu Pharmaceutical. Started Jun 2025; status: recruiting.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid polyneuropathy (ATTR-PN)
Beyond the preview
Go deeper on NCT06940336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940336.